Clustering of adverse events. An investigation was prompted when the U.S. Food and Drug Ad...

I

AGE

SEX

MANUF

DIAG

STAGE

TOX

DOSE

SCR

WEIGHT

GENERIC

1

50

1

J

1

1

1

36.0

0.8

66

1

2

21

1

J

1

2

2

29.0

1.1

68

1

3

35

1

J

2

2

2

16.2

0.7

97

1

4

49

2

S

1

1

2

29.0

0.8

83

2

5

38

1

J

2

2

1

16.2

1.4

97

1

6

42

1

S

2

2

2

18.0

1.0

82

2

7

17

1

J

1

2

2

17.4

1.0

64

1

8

20

1

S

2

2

2

17.4

1.0

73

2

9

49

2

J

1

1

2

37.2

0.7

103

1

10

41

2

J

1

2

2

18.6

0.9

58

1

11

20

1

S

2

2

2

18.0

1.1

113

2

12

55

1

S

1

1

2

36.0

0.8

87

2

13

44

2

J

1

1

1

22.4

1.2

59

1

14

23

1

S

2

2

2

39.6

0.8

83

2

15

64

2

S

1

1

2

30.0

0.9

69

2

16

65

1

S

1

1

1

23.2

1.7

106

2

17

23

2

S

1

2

2

16.8

0.9

66

2

18

44

1

S

1

2

2

17.4

1.0

84

2

19

29

2

S

2

1

2

18.0

0.7

56

2

20

32

1

S

1

2

2

18.0

1.0

84

2

21

18

1

S

2

2

2

17.4

0.9

70

2

22

22

1

S

1

1

1

26.1

1.7

69

2

23

43

2

J

2

2

2

18.0

0.8

63

1

24

39

2

S

1

2

2

18.0

0.9

55

2

25

38

2

J

1

1

1

16.0

1.0

112

1

Variable

Description

AGE

Age (years)

SEX

1 = male; 2 = female

MANUF

Manufacturer of the drug: Smith or Jones

DIAG

Underling diagnosis: 1 = leukemia; 2 = lymphoma

STAGE

Stage of disease: 1 = relapse; 2 = remission

TOX

Did cerebellar toxicity occur?: 1 = yes; 2 = no

DOSE

Dose of drug (g/m2)

SCR

Serum creatinine (mg/dl)

WEIGHT

Body weight (kg)

GENERIC

Generic drug: 1 = yes; 2 = no